NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
Mississauga, Ontario, July 6, 2023 – MyndTec Inc. (“MyndTec” or the “Company”) (CSE: MYTC), an emerging force in neurological treatment and rehabilitation, is pleased to announce that it has entered into a debt settlement agreement (the “Debt Settlement Agreement”) as of May 29, 2023, with an arm’s length creditor (the “Creditor”) to settle an outstanding debt in the amount of $756,120.56 (the “Debt”) (the “Transaction”). The Debt comprises the outstanding balance owed by the Company under a previous loan agreement (the “Loan Agreement”) between the Creditor and the Company.
Pursuant to the Debt Settlement Agreement, the parties entered into a subscription and debt to share conversion agreement, under which an aggregate amount of $378,061.60, comprising approximately 50% of the total amount of the Debt, will be satisfied in full and final settlement by the Company through the issuance and delivery of 540,088 fully paid common shares in the capital of the Company (the “Common Shares”) with an assigned issue price of $0.70 per share (the “Debt Shares”) (the “Shares For Debt Transaction”). The Debt Shares are being issued at a price equal to the closing market price of the Common Shares on the Canadian Securities Exchange (“CSE”) on July 5, 2023, being $0.70 per share, in accordance with the policies of the CSE.
Pursuant to the Debt Settlement Agreement, the parties also entered into a debt compromise and release agreement (the “Debt Compromise and Release Agreement”), under which an aggregate amount of $378,058.96, comprising approximately 50% of the total amount of the Debt, shall be compromised and forgiven by the Creditor, and the Company shall be forever discharged and released therefrom, effective on and as of May 29, 2024, conditional upon the Company failing, by such date, to commercialize the product developed from the proceeds of the loan advanced to the Company under the Loan Agreement (as further provided for in the Loan Agreement).
The board of directors of the Company has determined that it is in the best interests of the Company to settle the outstanding Debt by the issuance of the Common Shares in order to preserve the Company’s cash for ongoing operations.
Closing of the Shares For Debt Transaction is subject to customary closing conditions and intends to close as soon as practicable. The Debt Shares will be issued pursuant to a prospectus exemption and will be subject to a hold period of four months and a day from the date of issuance.
About MyndTec
MyndTec is a Canadian medical technology company dedicated to the development and commercialization of innovative products that improve function, maximize independence and enhance the quality of life for individuals who have suffered injury to the central nervous system as a result of stroke, spinal cord injury and certain traumatic brain injuries. The Company develops non-invasive neurological and nervous system electrical stimulation therapeutics for the treatment of neurological diseases and injury specifically targeted to markets with large, growing and global patient populations.
The Company’s flagship product MyndMove™ is a non-invasive functional electrical stimulation-based intervention. MyndMove™ uses neuroplasticity mechanisms to stimulate development of new neural efferent and afferent pathways allowing patients to re-establish voluntary movement and improve independence in their activities of daily living. The MyndMove™ system offers trained therapists the ability to assist individuals affected with paralysis to improve voluntary control of their limbs. The MyndMove™ therapy system offers a broad spectrum of sophisticated functional electrical stimulation software protocols which therapists customize to patient needs to enable meaningful controlled movements via proprietary stimulation technology.
For more information visit https://www.myndtec.com
Contact Information
Craig Leon
MyndTec Inc. | Chief Executive Officer
investor.relations@myndtec.com
Tel: (416) 569-0430
Bill Mitoulas
Venture North Capital Inc. | Principal
billm@venturenorthcapital.com
Tel: (416) 479-9547
Cautionary Note Regarding Forward-Looking Statements
The CSE has in no way passed upon the merits of the business of the Company and has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.